SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor is trending lower amid widespread bearish sentiment, with investors expressing frustration over recent price declines, year-end tax-loss harvesting, and management's communication approach. Despite this, a committed segment of the community remains bullish, pointing to the acquisition of Homebuyer.com, new CEO Kaz Nejatian's vision for AI integration and 2026 profitability, and anticipating a significant rebound.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is a hot topic due to a proposed merger with Applied Digital's cloud business, forming ChronoScale, an AI platform. This move has ignited significant community debate, with some anticipating a massive surge on AI momentum and a tight float. However, many current shareholders voice strong skepticism, highlighting their projected 3% ownership in the new entity as a highly unfavorable outcome.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

Mannatech Inc. ($MTEX) is experiencing heightened investor interest driven by its extremely low public float, leading to significant community speculation about a potential short squeeze and a parabolic breakout. While a strong bullish contingent anticipates substantial gains, others caution against a possible pump-and-dump given the rapid price action without immediate news. This discussion reflects a broader trend of retail traders targeting thinly traded micro-cap stocks for high-volatility, momentum-driven rallies.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending due to promising preliminary data from its FLAMINGO-01 breast cancer trial, which reported an 80% recurrence rate reduction, coupled with extended insider share lock-ups until 2026. The community is buzzing about the potential for a significant short squeeze, fueled by extremely high cost-to-borrow rates and the firm's long-term commitment to shareholder value without immediate dilution.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is experiencing significant discussion following recent positive Phase 3 data for relacorilant in platinum-resistant ovarian cancer, which showcased strong efficacy and a comparable safety profile, driving expectations for an upcoming regulatory filing. Community sentiment is highly optimistic about the drug's multi-billion dollar revenue potential and the possibility of a substantial short squeeze, though some anticipate near-term price consolidation after a rapid appreciation. Investors are also closely monitoring upcoming regulatory decisions for relacorilant in Cushing's syndrome and analyzing promising, yet mixed, survival data from its ALS program.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem is a key topic as it discontinues the RAMP 203 lung cancer trial to pivot resources toward the highly promising KRAS G12D inhibitor, VS-7375, following recent management changes aimed at accelerating growth. This move has polarized the community, with many seeing it as a strategic financial decision to focus on the most impactful pipeline asset, while others voice frustration over the resulting stock decline and concerns about market manipulation.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx (RARE) is heavily discussed as its shares reacted sharply to recent pharmaceutical developments. The company announced disappointing late-stage trial results for its brittle bone disease therapy, setrusumab, failing to meet its primary endpoint, alongside a Complete Response Letter from the FDA for its Sanfilippo syndrome treatment, UX111, citing manufacturing observations. While many investors express significant concern and exit positions, others view the stock as deeply oversold, emphasizing the company's existing revenue-generating portfolio and multiple other pipeline catalysts as grounds for a potential rebound.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust is highly trending following recent volatility attributed to increased margin requirements on precious metals, leading to forced liquidations and extensive profit-taking. The community is sharply divided, with bulls viewing the pullback as a buying opportunity driven by persistent industrial demand and upcoming export restrictions, while bears anticipate further correction after its rapid ascent.

ZEROBASE is a decentralized cryptographic infrastructure network that enables verifiable off-chain computation using zero-knowledge proofs (ZKPs) and trusted execution environments (TEEs).   It powers products like zkStaking, zkLogin, and ProofYield—bridging institutional DeFi, user privacy, and real-world asset strategies.   ZEROBASE delivers programmable, compliance-aligned staking and transparent cryptographic assurance without exposing sensitive data.

ZEROBASE

ZBT is trending as the crypto community enthusiastically discusses its new expanded availability on Binance, including Simple Earn and Margin trading, significantly boosting its accessibility. This development fuels strong bullish sentiment, with many viewing ZBT as a promising AI crypto play poised for future growth.

Featured in Matt Furies latest book Cortex Vortex as Ratos nemesis. The character is also part of ZOGZ which confirms its real name.  Matt Furie, the artist best known for creating Pepe the Frog, has been working on a new book. The news comes from his editor, who goes by the handle @beuys_on_sale_ on Instagram. In a recent post, the editor hinted at an upcoming project featuring new characters named Gasspas and Rato. Gasspas’s visual appearance can be inferred from the artwork. In one illustration, Gasspas is depicted looming over two rats (Rato and Wat), gazing down at them in a menacing way (an image that has circulated among collectors). This inferred that Gasspas is Ratos nemesis in the new book Cortex Vortex reinforced by community quips that “cats eat rats”. Gasspas debuted as part of ZOGZ, a collection of 111 original NFT character illustrations by Matt Furie launched in May 2023.

Gasspas

Gasspas (GASS) is trending amidst highly polarized community sentiment, with proponents highlighting its potential as a meme coin, sometimes linking it to PEPE's creator, and advocating to 'HODL' for significant gains. This bullish outlook is countered by strong skepticism from others who label it as 'junk' or a 'scam,' questioning its long-term viability and price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arcellx (NASDAQ:ACLX) Raised to "Strong-Buy" at Wells Fargo & Company

Wells Fargo & Company raised Arcellx to a "strong-buy" rating in a report on Monday...

Voya Investment Management LLC Reduces Stock Holdings in Arcellx, Inc. $ACLX

Voya Investment Management LLC reduced its position in shares of Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 10.3% in the 3rd quarter, according to the company in its most recent disclosure with the...

Arcellx, Inc. (NASDAQ:ACLX) Given Average Recommendation of "Moderate Buy" by Analysts

Arcellx, Inc. (NASDAQ:ACLX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten brokerages that are covering the stock, MarketBeat reports. One investment analyst...

Stempoint Capital LP Has $13.27 Million Stock Position in Arcellx, Inc. $ACLX

Stempoint Capital LP cut its stake in Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 26.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and...

Arcellx (NASDAQ:ACLX) Given Buy Rating at Canaccord Genuity Group

Canaccord Genuity Group reiterated a "buy" rating and set a $130.00 price objective on shares of Arcellx in a research note on Monday...

Arcellx (NASDAQ:ACLX) Shares Gap Up - Should You Buy?

Arcellx (NASDAQ:ACLX) Shares Gap Up - What's Next...

Arcellx (NASDAQ:ACLX) Given "Buy" Rating at Needham & Company LLC

Needham & Company LLC reaffirmed a "buy" rating and issued a $105.00 price objective on shares of Arcellx in a research report on Monday...

Arcellx (NASDAQ:ACLX) Stock Price Down 6.2% - Here's Why

Arcellx (NASDAQ:ACLX) Trading Down 6.2% - What's Next...

Russell Investments Group Ltd. Decreases Holdings in Arcellx, Inc. $ACLX

Russell Investments Group Ltd. lowered its holdings in Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 15.8% during the 2nd quarter, according to the company in its most recent disclosure with the...

Decheng Capital LLC Has $36.06 Million Stake in Arcellx, Inc. $ACLX

Decheng Capital LLC lifted its position in shares of Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 995.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange...

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

ACLX
Arcellx Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACLX News

ACLXArcellx Inc